Skip to main content
Premium Trial:

Request an Annual Quote

BioFocus to Screen Targets for CHDI

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BioFocus will perform drug-candidate screening and related services for the CHDI Foundation's Huntington's disease drug development programs under a five-year collaboration agreement, BioFocus' parent company Galapagos said today.

BioFocus will be eligible for up to $41 million in research fees over the course of the collaboration, for which it will use its full range of integrated drug discovery services. These discovery efforts will include neuronal assay development, high-content screening, fragment-based screening, computational chemistry, protein crystallography, as well as studies involving pharmacokinetics, absorption, distribution, metabolism, and elimination.

This agreement continues and expands a collaboration between the UK-based company and the non-profit institution that started in 2005.

"We are confident that the next five years of this long-standing relationship with CHDI will be as productive as the first five," Galapagos CEO Onno van de Stolpe said in a statement.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.